Literature DB >> 21844470

Melanoma occurring during treatment with fingolimod for multiple sclerosis: a case report.

Katrin Baumann Conzett, Isabel Kolm, Ilijas Jelcic, Jivko Kamarachev, Reinhard Dummer, Ralph Braun, Lars E French, Michael Linnebank, Günther F L Hofbauer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21844470     DOI： 10.1001/archdermatol.2011.212

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN： 0003-987X


× No keyword cloud information.
  9 in total

1.  The protumorigenic potential of FTY720 by promoting extramedullary hematopoiesis and MDSC accumulation.

Authors:  Y Li; T Zhou; Y Wang; C Ning; Z Lv; G Han; J C Morris; E N Taylor; R Wang; H Xiao; C Hou; Y Ma; B Shen; J Feng; R Guo; Y Li; G Chen
Journal:  Oncogene       Date:  2017-02-20       Impact factor: 9.867

2.  Detection of a new melanoma in a patient treated with fingolimod.

Authors:  Yves Michiels; Olivier Bugnon; Jean-François Michiels; Sophie Mazellier
Journal:  BMJ Case Rep       Date:  2019-04-29

Review 3.  Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis.

Authors:  Adnan M Subei; Daniel Ontaneda
Journal:  CNS Drugs       Date:  2015-09       Impact factor: 5.749

Review 4.  Cutaneous Adverse Effects of Neurologic Medications.

Authors:  Eman Bahrani; Chloe E Nunneley; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 6.497

Review 5.  The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod.

Authors:  Sathya Narayanan Patmanathan; Lee Fah Yap; Paul G Murray; Ian C Paterson
Journal:  J Cell Mol Med       Date:  2015-07-14       Impact factor: 5.310

6.  A multicentric pharmacovigilance study: collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients.

Authors:  Agnese Gugliandolo; Federica Longo; Maria Giovanna Marrosu; Giovanni Luigi Mancardi; Ilaria Gandoglia; Maurizio Melis; Fabrizio Lo Giudice; Placido Bramanti; Emanuela Mazzon
Journal:  Ther Clin Risk Manag       Date:  2018-09-26       Impact factor: 2.423

Review 7.  Patient experience and practice trends in multiple sclerosis - clinical utility of fingolimod.

Authors:  Jong-Mi Lee; May H Han
Journal:  Patient Prefer Adherence       Date:  2015-05-21       Impact factor: 2.711

8.  Multiple Sclerosis Treatment and Melanoma Development.

Authors:  Maria Luigia Carbone; Pedro Miguel Lacal; Serena Messinese; Laura De Giglio; Carlo Pozzilli; Severino Persechino; Cinzia Mazzanti; Cristina Maria Failla; Gianluca Pagnanelli
Journal:  Int J Mol Sci       Date:  2020-04-22       Impact factor: 5.923

9.  Exacerbation of Multiple Sclerosis by BRAF/MEK Treatment for Malignant Melanoma: The Central Vein Sign to Distinguish Demyelinating Lesions From Metastases.

Authors:  Christopher C Hemond; Rohit Bakshi; Shahamat Tauhid; Rosila Sarrosa; Madison Ryan; Vineetha Kamath; James Thomas; Keith R Edwards
Journal:  J Investig Med High Impact Case Rep       Date:  2021 Jan-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.